Michael Robert Martin - 10 Sep 2021 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role: Chief Business Officer
Signature: /s/ Michael Robert Martin
Issuer symbol: AUPH
Transactions as of: 10 Sep 2021
Net transactions value: -$1,887,217
Form type: 4
Filing time: 14 Sep 2021, 18:16:31 UTC
Previous filing: 08 Sep 2021
Next filing: 16 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AUPH	Common Shares	Options Exercise	$132,500	+25,000	+14%	$5.30	201,861	13 Sep 2021	Direct	F1
transaction	AUPH	Common Shares	Sale	$495,000	-25,000	-12%	$19.80	176,861	10 Sep 2021	Direct	F2, F3
transaction	AUPH	Common Stock	Options Exercise	$238,500	+45,000	+25%	$5.30	221,861	14 Sep 2021	Direct	F1
transaction	AUPH	Common Stock	Options Exercise	$144,000	+45,000	+20%	$3.20	266,861	14 Sep 2021	Direct	F1
transaction	AUPH	Common Stock	Sale	$1,907,217	-90,000	-34%	$21.19	176,861	14 Sep 2021	Direct	F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AUPH	Option Grant (right to buy)	Options Exercise	$0	-25,000	-17%	$0.000000	125,000	13 Sep 2021	Common Stock	25,000	$5.30	Direct	F1, F6
transaction	AUPH	Option Grant (right to buy)	Options Exercise	$0	-45,000	-36%	$0.000000	80,000	14 Sep 2021	Common Stock	45,000	$5.30	Direct	F1, F7
transaction	AUPH	Option Grant (right to buy)	Options Exercise	$0	-45,000	-50%	$0.000000	45,000	14 Sep 2021	Common Stock	45,000	$3.20	Direct	F1, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3	The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $19.76 to $19.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in connection with a divorce settlement agreement.
F5	The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $21.00 to $21.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F6	The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.
F7	The shares subject to the option vest in thirty-six equal monthly installments from the grant date.
F8	The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.